Phase II trial of concomitant low dose temozolomide with external beam radiation (EBRT) followed by 12 months of temozolomide and irinotecan for newly diagnosed glioblastoma (GBM): Preliminary results of RTOG 04-20

Frank S. Lieberman,Christina Tsien,B. Berkey,Walter J. Curran,Maria Werner-Wasik,Ryan P. Smith,L. Grossheim,E. Hug,M. Mehta

Phase II trial of concomitant low dose temozolomide with external beam radiation (EBRT) followed by 12 months of temozolomide and irinotecan for newly diagnosed glioblastoma (GBM): Preliminary results of RTOG 04-20

2006

Frank S. Lieberman
Christina Tsien
B. Berkey
Walter J. Curran
Maria Werner-Wasik
Ryan P. Smith
L. Grossheim
E. Hug
M. Mehta

1510 Background: Irinotecan and temozolomide compare favorably to regimens tested in recurrent GBM. RTOG 04–20 intensifies the Stupp R, et al. (N Engl J Med. 2005 Mar 10;352(10):987–96) adjuvant re...

Keywords:

Cancer research
Glioblastoma
Temozolomide
Radiation
Medicine
Irinotecan
external beam radiation
Oncology
Internal medicine
Adjuvant
newly diagnosed
low dose
Concomitant
Pathology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations